Compare CLAR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | ZNTL |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.8M | 118.3M |
| IPO Year | N/A | 2020 |
| Metric | CLAR | ZNTL |
|---|---|---|
| Price | $3.39 | $1.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.33 | ★ $5.87 |
| AVG Volume (30 Days) | 132.2K | ★ 508.5K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,432,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $1.01 |
| 52 Week High | $5.08 | $3.33 |
| Indicator | CLAR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 42.04 |
| Support Level | $3.33 | $1.34 |
| Resistance Level | $3.71 | $1.45 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 11.84 | 14.71 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.